Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $210.35 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Myriad Genetics Stock Performance

Shares of NASDAQ:MYGN opened at $14.19 on Monday. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -10.92 and a beta of 1.88. Myriad Genetics has a 52 week low of $12.04 and a 52 week high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average of $13.45 and a 200 day moving average of $19.48.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. The Goldman Sachs Group reduced their price target on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Bank of America reduced their price target on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. StockNews.com downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Craig Hallum assumed coverage on Myriad Genetics in a research report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price target on the stock. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $22.54.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.